BTK and B-cell chronic lymphocytic leukemia: An explanation for the modest in vivo activity in AML models could be the fact that ARQ 531 activity against AML potentially needs a constant steady-state plasma concentration (Css) in the μM range unlike in CLL where BTK phosphorylation inhibition is achieved in nM range.